SCHEMBL284851

SCHEMBL284851

CC(=O)Oc1ccc2c(c1)Oc1cc(OC(C)=O)ccc1C21OC(=O)c2c1ccc(Cl)c2Cl

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.65
MEN1 O00255 3/20 0.65
KMT2A Q03164 3/20 0.65
ALDH1A1 P00352 3/20 0.65
HTT P42858 2/20 0.65
USP2 O75604 2/20 0.65
LMNA P02545 1/20 0.65
GSTP1 P09211 1/20 0.61
CYP3A4 P08684 1/20 0.43
FTO Q9C0B1 4/20 0.39
HPGD P15428 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
RECQL P46063 2/20 0.38
CYP2C19 P33261 1/20 0.38
BLM P54132 1/20 0.38
SMAD3 P84022 1/20 0.38
PRMT1 Q99873 1/20 0.38
ACE2 Q9BYF1 1/20 0.38
CYP2C9 P11712 1/20 0.37
ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1703820 0.95 MAPT (0.59) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL5445148 0.89 MEN1 (0.68) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL4632262 0.87 MEN1 (0.49) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL7575984 0.85 MAPT (0.60) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL18009919 0.83 MAPT (0.66) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL3248111 0.82 GSTP1 (0.67) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL19549151 0.82 MEN1 (0.42) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL1029702 0.81 ALDH1A1 (0.67) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL6523127 0.80 MAPT (0.62) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL9561179 0.80 ALDH1A1 (0.62) MAPTMEN1KMT2AALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024117691-A1 GOLD NANOZYME COMPRISING GLYCOL CHITOSAN AND GOLD PARTICLES, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE COMPRISING SAME 한양대학교 산학협력단 2024-06-06 WO disclosed
US-20230407238-A1 USE OF HYALURONIC ACID OR SALT THEREOF AND/OR TREHALOSE IN STABILIZING ERGOTHIONEINE, AND ERGOTHIONEINE COMPOSITION CONTAINING HYALURONIC ACID OR SALT THEREOF AND/OR TREHALOSE BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED (CN) 2023-12-21 US disclosed
CN-114904012-B Active oxygen self-supplementing amphiphilic block copolymer-drug conjugate, preparation method and application thereof 四川大学华西医院 2023-12-15 CN disclosed
EP-4245304-A1 USE OF HYALURONIC ACID OR SALT THEREOF AND/OR TREHALOSE IN STABILIZING ERGOTHIONEINE, AND ERGOTHIONEINE COMPOSITION CONTAINING HYALURONIC ACID OR SALT THEREOF AND/OR TREHALOSE Bloomage Biotechnology Corporation Limited (CN) 2023-09-20 EP disclosed
CN-114904012-A Active oxygen self-complementary amphiphilic block copolymer-drug conjugate, preparation method and application thereof 四川大学华西医院 2022-08-16 CN disclosed
US-20200316129-A1 ENGINEERED ANUCLEATE CELLULAR AND EXTRACELLULAR VESICLES AS A NOVEL BIOLOGICS DELIVERY PLATFORM THE JOHNS HOPKINS UNIVERSITY 2020-10-08 US disclosed
WO-2017205559-A1 ENGINEERED ANUCLEATE CELLULAR AND EXTRACELLULAR VESICLES AS A NOVEL BIOLOGICS DELIVERY PLATFORM THE JOHNS HOPKINS UNIVERSITY (US) 2017-11-30 WO disclosed
CN-106794123-A The composition of the material of the expression comprising regulation ABH antigens 株式会社爱茉莉太平洋 2017-05-31 CN disclosed
US-20160375107-A1 FRAGILE HISTIDINE TRIAD (FHIT) COMPOSITIONS AND USES THEREOF THE OHIO STATE UNIVERSITY (US) 2016-12-29 US disclosed
EP-2428208-B1 Method of determining the potency of pharmaceutical substances to reduce the cellular glutathion content and to increase the cellular ROS content EBERHARD KARLS UNIVERSITÄT TÜBINGEN UNIVERSITÄTSKLINIKUM (DE) 2016-11-30 EP disclosed
WO-2009122447-A1 SEMI-SYNTHETIC SESQUITERPENE LACTONE PARTHENIN COMPOUND USEFUL FOR CYTOTOXICITY AGAINST CANCER CELL LINES AND ANTICANDER AGENT COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2009-10-08 WO disclosed
EP-2104533-A2 USE OF SUBSTANCES REDUCING CELLULAR GLUTATHIONE CONTENT FOR PRODUCING A MEDICAMENT FOR TREATING T-CELL MEDIATED AUTOIMMUNE DISEASES Eberhard-Karls-Universität Tübingen (DE) 2009-09-30 EP disclosed
WO-2009055773-A2 METHODS FOR IDENTIFYING FRAGILE HISTIDINE TRIAD (FHIT) INTERACTION AND USES THEREOF THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2009-04-30 WO disclosed
WO-2008064756-A2 USE OF SUBSTANCES REDUCING CELLULAR GLUTATHIONE CONTENT FOR PRODUCING A MEDICAMENT FOR TREATING T-CELL MEDIATED AUTOIMMUNE DISEASES Eberhard-Karls-Universität Tübingen (DE) 2008-06-05 WO disclosed
EP-0723778-B1 Composition for induction of apoptosis comprising a factor increasing the intracellular level of methional or malondialdehyde INT DE CENTRE (FR) 2000-04-05 EP disclosed
WO-1999033463-A9 SESQUITERPENE LACTONES SPECIFICALLY INHIBIT ACTIVATION OF NF-λB BY PREVENTING THE DEGRADATION OF IλB-α AND IλB-$g(b) MOSER RENE (CH) 1999-09-23 WO disclosed
WO-1999033463-A1 SESQUITERPENE LACTONES SPECIFICALLY INHIBIT ACTIVATION OF NF-λB BY PREVENTING THE DEGRADATION OF IλB-α AND IλB-$g(b) Moser, René (CH) 1999-07-08 WO disclosed
US-5744499-A Apoptosis-modulating factors influencing the intracellular concentration of methional/malondialdehyde CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 1998-04-28 US disclosed
EP-0723778-A1 Composition for modulation of apoptosis comprising a factor influencing the intracellular level of methional or malondialdehyde CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) 1996-07-31 EP disclosed
WO-1996020701-A1 APOPTOSIS-MODULATING COMPOSITION COMPRISING A FACTOR AFFECTING THE INTRACELLULAR RATE OF METHIONAL OR MALONDIALDEHYDE CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) 1996-07-11 WO disclosed